APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cholesterol-Lowering Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cholesterol-Lowering Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025195 pages

Choose your research edition.

Industry ResearchCholesterol-Lowering Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Cholesterol-Lowering Drugs Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Cholesterol-Lowering Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cholesterol-Lowering Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Cholesterol-Lowering Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Cholesterol-Lowering Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cholesterol-Lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cholesterol-Lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cholesterol-Lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cholesterol-Lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cholesterol-Lowering Drugs include Sanofi, Novartis, Merck, Pfizer, Daiichi Sankyo, Amgen, AbbVie, AstraZeneca and Kowa, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cholesterol-Lowering Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cholesterol-Lowering Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cholesterol-Lowering Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cholesterol-Lowering Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cholesterol-Lowering Drugs Segment by Company

Sanofi

Novartis

Merck

Pfizer

Daiichi Sankyo

Amgen

AbbVie

AstraZeneca

Kowa

Bristol-Myers Squibb

Cholesterol-Lowering Drugs Segment by Type

PCSK9 Inhibitors

Fibrates

Cholesterol Absorption Inhibitors

Statins

Cholesterol-Lowering Drugs Segment by Application

Hospital

Household

Other

Cholesterol-Lowering Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cholesterol-Lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cholesterol-Lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cholesterol-Lowering Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cholesterol-Lowering Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cholesterol-Lowering Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cholesterol-Lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cholesterol-Lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cholesterol-Lowering Drugs Industry Trends Table 2. Cholesterol-Lowering Drugs Industry Drivers Table 3. Cholesterol-Lowering Drugs Industry Opportunities and Challenges Table 4. Cholesterol-Lowering Drugs Industry Restraints Table 5. Global Cholesterol-Lowering Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cholesterol-Lowering Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cholesterol-Lowering Drugs Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Cholesterol-Lowering Drugs Sales Market Share by Manufacturers Table 9. Global Cholesterol-Lowering Drugs Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Cholesterol-Lowering Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cholesterol-Lowering Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cholesterol-Lowering Drugs Manufacturers, Product Type & Application Table 13. Global Cholesterol-Lowering Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cholesterol-Lowering Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of PCSK9 Inhibitors Table 17. Major Manufacturers of Fibrates Table 18. Major Manufacturers of Cholesterol Absorption Inhibitors Table 19. Major Manufacturers of Statins Table 20. Global Cholesterol-Lowering Drugs Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 21. Global Cholesterol-Lowering Drugs Sales by Type (2021-2026) & (k tons) Table 22. Global Cholesterol-Lowering Drugs Sales by Type (2027-2032) & (k tons) Table 23. Global Cholesterol-Lowering Drugs Sales Market Share by Type (2021-2026) Table 24. Global Cholesterol-Lowering Drugs Sales Market Share by Type (2027-2032) Table 25. Global Cholesterol-Lowering Drugs Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 26. Global Cholesterol-Lowering Drugs Revenue by Type (2021-2026) & (k tons) Table 27. Global Cholesterol-Lowering Drugs Revenue by Type (2027-2032) & (k tons) Table 28. Global Cholesterol-Lowering Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Cholesterol-Lowering Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Household Table 32. Major Manufacturers of Other Table 33. Global Cholesterol-Lowering Drugs Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 34. Global Cholesterol-Lowering Drugs Sales by Application (2021-2026) & (k tons) Table 35. Global Cholesterol-Lowering Drugs Sales by Application (2027-2032) & (k tons) Table 36. Global Cholesterol-Lowering Drugs Sales Market Share by Application (2021-2026) Table 37. Global Cholesterol-Lowering Drugs Sales Market Share by Application (2027-2032) Table 38. Global Cholesterol-Lowering Drugs Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 39. Global Cholesterol-Lowering Drugs Revenue by Application (2021-2026) & (k tons) Table 40. Global Cholesterol-Lowering Drugs Revenue by Application (2027-2032) & (k tons) Table 41. Global Cholesterol-Lowering Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Cholesterol-Lowering Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Cholesterol-Lowering Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 44. Global Cholesterol-Lowering Drugs Sales by Region (2021-2026) & (k tons) Table 45. Global Cholesterol-Lowering Drugs Sales Market Share by Region (2021-2026) Table 46. Global Cholesterol-Lowering Drugs Sales Forecasted by Region (2027-2032) & (k tons) Table 47. Global Cholesterol-Lowering Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 49. North America Cholesterol-Lowering Drugs Sales by Country (2021-2026) & (k tons) Table 50. North America Cholesterol-Lowering Drugs Sales by Country (2027-2032) & (k tons) Table 51. Europe Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 52. Europe Cholesterol-Lowering Drugs Sales by Country (2021-2026) & (k tons) Table 53. Europe Cholesterol-Lowering Drugs Sales by Country (2027-2032) & (k tons) Table 54. Asia Pacific Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 55. Asia Pacific Cholesterol-Lowering Drugs Sales by Country (2021-2026) & (k tons) Table 56. Asia Pacific Cholesterol-Lowering Drugs Sales by Country (2027-2032) & (k tons) Table 57. South America, Middle East and Africa Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 58. South America, Middle East and Africa Cholesterol-Lowering Drugs Sales by Country (2021-2026) & (k tons) Table 59. South America, Middle East and Africa Cholesterol-Lowering Drugs Sales by Country (2027-2032) & (k tons) Table 60. Global Cholesterol-Lowering Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Cholesterol-Lowering Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Cholesterol-Lowering Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Cholesterol-Lowering Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Cholesterol-Lowering Drugs Revenue Market Share by Region (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sanofi Cholesterol-Lowering Drugs Product Portfolio Table 69. Sanofi Recent Development Table 70. Novartis Company Information Table 71. Novartis Business Overview Table 72. Novartis Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novartis Cholesterol-Lowering Drugs Product Portfolio Table 74. Novartis Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck Cholesterol-Lowering Drugs Product Portfolio Table 79. Merck Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer Cholesterol-Lowering Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. Daiichi Sankyo Company Information Table 86. Daiichi Sankyo Business Overview Table 87. Daiichi Sankyo Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Daiichi Sankyo Cholesterol-Lowering Drugs Product Portfolio Table 89. Daiichi Sankyo Recent Development Table 90. Amgen Company Information Table 91. Amgen Business Overview Table 92. Amgen Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Amgen Cholesterol-Lowering Drugs Product Portfolio Table 94. Amgen Recent Development Table 95. AbbVie Company Information Table 96. AbbVie Business Overview Table 97. AbbVie Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. AbbVie Cholesterol-Lowering Drugs Product Portfolio Table 99. AbbVie Recent Development Table 100. AstraZeneca Company Information Table 101. AstraZeneca Business Overview Table 102. AstraZeneca Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. AstraZeneca Cholesterol-Lowering Drugs Product Portfolio Table 104. AstraZeneca Recent Development Table 105. Kowa Company Information Table 106. Kowa Business Overview Table 107. Kowa Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Kowa Cholesterol-Lowering Drugs Product Portfolio Table 109. Kowa Recent Development Table 110. Bristol-Myers Squibb Company Information Table 111. Bristol-Myers Squibb Business Overview Table 112. Bristol-Myers Squibb Cholesterol-Lowering Drugs Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Bristol-Myers Squibb Cholesterol-Lowering Drugs Product Portfolio Table 114. Bristol-Myers Squibb Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Cholesterol-Lowering Drugs Distributors List Table 118. Cholesterol-Lowering Drugs Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Cholesterol-Lowering Drugs Product Image Figure 2. Global Cholesterol-Lowering Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cholesterol-Lowering Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Cholesterol-Lowering Drugs Sales (2021-2032) & (k tons) Figure 5. Global Cholesterol-Lowering Drugs Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Cholesterol-Lowering Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. PCSK9 Inhibitors Image Figure 9. Fibrates Image Figure 10. Cholesterol Absorption Inhibitors Image Figure 11. Statins Image Figure 12. Global Cholesterol-Lowering Drugs Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 13. Global Cholesterol-Lowering Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Cholesterol-Lowering Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Cholesterol-Lowering Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 16. Global Cholesterol-Lowering Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cholesterol-Lowering Drugs Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Household Image Figure 20. Other Image Figure 21. Global Cholesterol-Lowering Drugs Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 22. Global Cholesterol-Lowering Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Cholesterol-Lowering Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Cholesterol-Lowering Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 25. Global Cholesterol-Lowering Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Cholesterol-Lowering Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 28. North America Cholesterol-Lowering Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 30. Canada Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 31. Mexico Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 32. Europe Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Europe Cholesterol-Lowering Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 35. France Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 36. U.K. Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 37. Italy Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 38. Netherlands Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 39. Asia Pacific Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Asia Pacific Cholesterol-Lowering Drugs Sales Market Share by Country (2021-2032) Figure 41. China Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 42. Japan Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 43. South Korea Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 44. Southeast Asia Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 45. India Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 46. Australia Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 47. South America, Middle East and Africa Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 48. South America, Middle East and Africa Cholesterol-Lowering Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 50. South Africa Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 51. Saudi Arabia Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 52. Turkey Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 53. Argentina Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 54. UAE Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 55. Egypt Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Chile Cholesterol-Lowering Drugs Sales and Growth Rate (2021-2032) & (k tons) Figure 57. Global Cholesterol-Lowering Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Cholesterol-Lowering Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Cholesterol-Lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Cholesterol-Lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Cholesterol-Lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Cholesterol-Lowering Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Cholesterol-Lowering Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Cholesterol-Lowering Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • PCSK9 Inhibitors
  • Fibrates
  • Cholesterol Absorption Inhibitors
  • Statins
Applications
  • Hospital
  • Household
  • Other
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Pfizer
  • Daiichi Sankyo
  • Amgen
  • AbbVie
  • AstraZeneca
  • Kowa
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cholesterol-Lowering Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cholesterol-Lowering Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cholesterol-Lowering Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cholesterol-Lowering Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cholesterol-Lowering Drugs Market Dynamics
  1. 2.1 Cholesterol-Lowering Drugs Industry Trends
  2. 2.2 Cholesterol-Lowering Drugs Industry Drivers
  3. 2.3 Cholesterol-Lowering Drugs Industry Opportunities and Challenges
  4. 2.4 Cholesterol-Lowering Drugs Industry Restraints
3 Cholesterol-Lowering Drugs Market by Manufacturers
  1. 3.1 Global Cholesterol-Lowering Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cholesterol-Lowering Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cholesterol-Lowering Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cholesterol-Lowering Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cholesterol-Lowering Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cholesterol-Lowering Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Cholesterol-Lowering Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cholesterol-Lowering Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cholesterol-Lowering Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cholesterol-Lowering Drugs Tier 1, Tier 2, and Tier 3
4 Cholesterol-Lowering Drugs Market by Type
  1. 4.1 Cholesterol-Lowering Drugs Type Introduction
  2. 4.1.1 PCSK9 Inhibitors
  3. 4.1.2 Fibrates
  4. 4.1.3 Cholesterol Absorption Inhibitors
  5. 4.1.4 Statins
  6. 4.2 Global Cholesterol-Lowering Drugs Sales by Type
  7. 4.2.1 Global Cholesterol-Lowering Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cholesterol-Lowering Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Cholesterol-Lowering Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Cholesterol-Lowering Drugs Revenue by Type
  11. 4.3.1 Global Cholesterol-Lowering Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cholesterol-Lowering Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Cholesterol-Lowering Drugs Revenue Market Share by Type (2021-2032)
5 Cholesterol-Lowering Drugs Market by Application
  1. 5.1 Cholesterol-Lowering Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Household
  4. 5.1.3 Other
  5. 5.2 Global Cholesterol-Lowering Drugs Sales by Application
  6. 5.2.1 Global Cholesterol-Lowering Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cholesterol-Lowering Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Cholesterol-Lowering Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cholesterol-Lowering Drugs Revenue by Application
  10. 5.3.1 Global Cholesterol-Lowering Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cholesterol-Lowering Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Cholesterol-Lowering Drugs Revenue Market Share by Application (2021-2032)
6 Global Cholesterol-Lowering Drugs Sales by Region
  1. 6.1 Global Cholesterol-Lowering Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cholesterol-Lowering Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cholesterol-Lowering Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Cholesterol-Lowering Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cholesterol-Lowering Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cholesterol-Lowering Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cholesterol-Lowering Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cholesterol-Lowering Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cholesterol-Lowering Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cholesterol-Lowering Drugs Revenue by Region
  1. 7.1 Global Cholesterol-Lowering Drugs Revenue by Region
  2. 7.1.1 Global Cholesterol-Lowering Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cholesterol-Lowering Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Cholesterol-Lowering Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Cholesterol-Lowering Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cholesterol-Lowering Drugs Revenue (2021-2032)
  8. 7.2.2 North America Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cholesterol-Lowering Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cholesterol-Lowering Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cholesterol-Lowering Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cholesterol-Lowering Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Cholesterol-Lowering Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Cholesterol-Lowering Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Cholesterol-Lowering Drugs Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Cholesterol-Lowering Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Daiichi Sankyo
  26. 8.5.1 Daiichi Sankyo Company Information
  27. 8.5.2 Daiichi Sankyo Business Overview
  28. 8.5.3 Daiichi Sankyo Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Daiichi Sankyo Cholesterol-Lowering Drugs Product Portfolio
  30. 8.5.5 Daiichi Sankyo Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Cholesterol-Lowering Drugs Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Cholesterol-Lowering Drugs Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Cholesterol-Lowering Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Kowa
  50. 8.9.1 Kowa Company Information
  51. 8.9.2 Kowa Business Overview
  52. 8.9.3 Kowa Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kowa Cholesterol-Lowering Drugs Product Portfolio
  54. 8.9.5 Kowa Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Cholesterol-Lowering Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Cholesterol-Lowering Drugs Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cholesterol-Lowering Drugs Value Chain Analysis
  2. 9.1.1 Cholesterol-Lowering Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cholesterol-Lowering Drugs Production Mode & Process
  6. 9.2 Cholesterol-Lowering Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cholesterol-Lowering Drugs Distributors
  9. 9.2.3 Cholesterol-Lowering Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst